XNYSELAN
Market cap5.96bUSD
Dec 26, Last price
12.05USD
1D
1.43%
1Q
-15.85%
IPO
-64.66%
Name
Elanco Animal Health Inc
Chart & Performance
P/E
—
P/S
1.35
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.43%
Rev. gr., 5y
7.57%
Revenues
4.42b
-0.02%
Net income
-1.23b
L+1,563.51%
CFO
271m
-40.04%
Earnings
Feb 24, 2025
Profile
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. The company is headquartered in Greenfield, Indiana and currently employs 5,590 full-time employees. The firm offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The company provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The company also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The company also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. The company also provides products in poultry and aquaculture production.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 4,417,000 -0.02% | 4,418,000 -7.28% | 4,765,000 45.57% | ||||||
Cost of revenue | 4,086,000 | 3,500,000 | 3,907,000 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 331,000 | 918,000 | 858,000 | ||||||
NOPBT Margin | 7.49% | 20.78% | 18.01% | ||||||
Operating Taxes | 36,000 | 8,000 | (95,000) | ||||||
Tax Rate | 10.88% | 0.87% | |||||||
NOPAT | 295,000 | 910,000 | 953,000 | ||||||
Net income | (1,231,000) 1,563.51% | (74,000) -84.32% | (472,000) -15.73% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 38,000 | 388,000 | 294,000 | ||||||
Long-term debt | 5,956,000 | 5,559,000 | 6,152,000 | ||||||
Deferred revenue | 271,000 | ||||||||
Other long-term liabilities | 485,000 | 390,000 | 261,000 | ||||||
Net debt | 5,616,000 | 5,565,000 | 5,778,000 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 271,000 | 452,000 | 483,000 | ||||||
CAPEX | (140,000) | (184,000) | (197,000) | ||||||
Cash from investing activities | (169,000) | (179,000) | (530,000) | ||||||
Cash from financing activities | (83,000) | (549,000) | 210,000 | ||||||
FCF | 36,000 | 641,000 | 1,308,600 | ||||||
| Balance | |||||||||
Cash | 352,000 | 345,000 | 638,000 | ||||||
Long term investments | 26,000 | 37,000 | 30,000 | ||||||
Excess cash | 157,150 | 161,100 | 429,750 | ||||||
Stockholders' equity | (2,554,000) | (1,449,000) | (1,158,000) | ||||||
Invested Capital | 15,146,000 | 14,964,000 | 15,547,000 | ||||||
ROIC | 1.96% | 5.97% | 6.15% | ||||||
ROCE | 2.52% | 6.48% | 5.67% | ||||||
| EV | |||||||||
Common stock shares outstanding | 492,300 | 488,300 | 487,200 | ||||||
Price | 14.90 21.93% | 12.22 -56.94% | 28.38 -7.47% | ||||||
Market cap | 7,335,270 22.93% | 5,967,026 -56.84% | 13,826,736 2.13% | ||||||
EV | 12,951,270 | 11,532,026 | 19,604,736 | ||||||
EBITDA | 1,025,000 | 1,600,000 | 1,574,000 | ||||||
EV/EBITDA | 12.64 | 7.21 | 12.46 | ||||||
Interest | 277,000 | 241,000 | 236,000 | ||||||
Interest/NOPBT | 83.69% | 26.25% | 27.51% | ||||||